Semiotics' microarrays for blood tests got the second investment tranche

RVC's Biofund, an RVC OJSC Portfolio Fund, in partnership with IR Russ-Invest made a decision to continue financing the company and to provide the second tranche to Semiotics Company specializing in the design and manufacture of unique microarrays for blood and plasma donation analysis. The total tranche volume is 144 million rubles.

The Board of Directors of Semiotics Company approved the main directions of the project development for 2014-2015 year, which focuses on completion of the first commercial microarray version and organization of industrial production on the "Moscow" technopolis territory. The microarray initial batch release is expected in the first quarter of 2015.

The first Semiotics' product is a microarray designed to detect any pathogens and oncomarkers in the blood. Semiotics relies on multiplex analysis, as well as high levels of analysis sensitivity and specificity. The microarray version under development will allow to simultaneously detect 10 different pathogens and implement oncodiagnostics based on the determination of tumor-specific antibodies to two tumors types.

The microarray initial batch will be sent to Basel University Hospital (Department of Biomedicine) for ovarian cancer research, as well as to GlycoTech which sells reagents and materials for glycobiological studies in the United States.